3Daughters Announces NIH to Support Testing of Novel Frameless Magnetic Copper IUD (3D-001) for Contraception
September 25 2024 - 8:00AM
3Daughters, Inc., a clinical development company fueling
evolutionary healthcare for women, announced the Eunice Kennedy
Shriver National Institute of Child Health and Human Development
(NICHD) at the National Institutes of Health (NIH) will support
testing to evaluate 3Daughters’ novel frameless, magnetic, copper
intrauterine device (IUD) for female contraception at NICHD’s
Biological Testing Facility. The facility supports research for the
optimization of male and female contraceptive agents, particularly
biologic studies for preclinical development and advancement.
"We are incredibly honored to receive this support from the NIH
at this point in our clinical development, which reaffirms the
transformative potential of our frameless, magnetic copper IUD for
female contraception," commented Mary Beth Cicero, CEO of
3Daughters. "We are committed to women’s health innovation, and to
offering a new contraceptive option that meets the needs of women.
With all the media exposure surrounding IUD insertion pain, our
integrated system of an IUD and Slider™ (inserter/retriever) is
directed to literally address the ‘pain points’ women experience
with current IUDs. We are continuing to advance our program for
3D-001 and are poised to be in the clinic next year.”
William Bracken, PhD, Head of Toxicology at 3Daughters and
Primary Investigator for the study, stated, "This preclinical
research will provide essential data on the copper release kinetics
and inflammatory responses of 3D-001 compared to existing copper
IUDs. We expect to significantly add to our understanding of how
copper functions as a spermicide and potentially how a frameless
design could be beneficial compared to the traditional T-shaped
devices."
The 3Daughters IUD is comprised of three small ellipses encased
in copper that self-assemble into a stable triad formation upon
insertion into the uterus. The triad is expected to float gently in
the uterus, not requiring placement between the fallopian tubes
like the T-shaped IUDs. The free-floating nature of 3D-001 could be
important for copper release characteristics and product
performance. Ms. Cicero further added, “We would like to
acknowledge the foresight of NICHD in having a program for
early-stage contraceptive testing.”
3Daughters is raising a Series A of $15 million to fund a Phase
1 clinical trial and is preparing to submit an IND in 2025.
About 3Daughters™3Daughters is a clinical
development company focused on evolutionary healthcare for women
where cutting-edge research and innovation is desperately needed.
The Company’s technology platform is based on physics and geometry
to deliver targeted therapy to the uterus. The first product,
(3D-001), is a frameless, magnetic, non-hormonal intrauterine
device (IUD) for long-acting contraception that conforms to a
woman’s body. Combined with our unique, patented Slider™ system
(for insertion and retrieval), this integrated system is expected
to eliminate the most painful steps in the insertion process as
well as the nuisance factor of strings (needed for removal).
3Daughters’ vision is to solve health issues for women,
particularly significant, and neglected, problems. 3Daughters plans
to radically disrupt the IUD market by addressing the major
adoption barrier — insertion pain. This pain is associated with all
current rigid, plastic T-shape framed IUDs and prevents women from
selecting one of the most effective forms of birth control.
Visit 3daughtershealth.com for more information.
Contact
Louis Scotti
Senior Vice President, Business Operations & Corporate Development
lscotti@3daughtershealth.com